anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, phytotherapy, pharmacy. SUBSTANCE: invention relates to design species prepared of medicinal plant raw used as cholagogue agents. Proposed species has sandy common immortelle flowers, peppermint leaves, sown coriander fruits, birch leaves, tansy flowers, dandelion roots, officinalis matricary flowers, dill seeds, swamp wild rosemary sprouts, maize stigmas and common centaury herb taken in the definite ratio of components. Claimed species stimulates proliferation of new hepatocytes, dilutes bile, dissolves pigment component of gall stones, normalizes gall bladder function and so on. EFFECT: enhanced effectiveness of species. 1 cl, 2 ex
The study was planned in a randomized controlled study design to determine the effect of kinesio taping applied to women who gave birth by cesarean section on acute pain, comfort level and breastfeeding behavior. The study will be carried out at Hacettepe University Adult Hospital. The universe of the research will be women who gave birth by cesarean section at Hacettepe University Adult Hospital during the study. Women who are planned for a cesarean section, meet the inclusion criteria and volunteer, will be informed about the practice and will be included in the sample of the research. There will be two groups assigned by the randomization method in the study. The number of samples to be recruited into the control and intervention groups was determined by a statistician using the G\*Power 3.1.9.4 package program, based on studies in Turkish culture and studies evaluating pain and breastfeeding in women who underwent kinesio taping on the abdominal and breast regions, and the sample size was determined by each of the kinesio taping and control groups. It is planned that 24 women will be formed in one of them, 48 women in total. In addition to routine treatment and care, kinesio taping will be applied to women in the intervention group; the control group will receive only routine treatment and care. The data of the research; "Information Form on Descriptive Characteristics", "Breastfeeding Diagnosis and Evaluation Measurement Tool (LATCH)", "Postpartum Breastfeeding Self-Efficacy Scale" and "Postpartum Comfort Scale", "Visual Analog Scale (Postpartum Breastfeeding Self-Efficacy Scale)" VAS)'' will be collected using the "Mother Follow-up Form". In the analysis of data; in qualitative variables according to descriptive statistics (mean, standard deviation, frequency) and normal distribution of data; Chi-square test, Fisher's exact test, numerical variables; Student's t test, Mann Whitney U test, one-way analysis of variance (ANOVA) and Kruskal Wallis Analysis will be used. Before and after repeated measurements, one-way analysis of variance or Wilcoxon t test will be used according to the normal distribution. At the end of the research, it is expected that the kinesio taping applied after the cesarean section will make a positive contribution to reducing the pain level of the mother, increasing the success of breastfeeding and improving the comfort level.
The invention relates to immunopotentiator proline-glycocoll cyclic tetrapeptide (C14H20N404). The compound is obtained by the fermentation and separation of microorganism Bacillussimplex DR-834. As shown by numerous tests, the compound can be used for preparing drugs for enhancing the immune function of animals such aquatic animal fish. A crude fermentation product of the Bacillussimplex DR-834 containing cyclic tetrapeptide can be used as feedstuff. By using the proline-glycocoll cyclic tetrapeptide, the mRNA (Messenger RNA) expression level of interleukin 1-beta gene and nitric oxide synthase in blood is obviously increased compared with contrast, and the immunity of aquatic animals can be obviously improved. The result of a virus attacking test indicates that the cyclic tetrapeptide is remarkable in immune protection. In test groups, the average death rate is 26.67%, and the rate of a contrast group is 73.33% and the relative immune protection rate of the contrast group is 63.63%.
The invention discloses compound essential oil for treating upper respiratory discomfort. The compound essential oil is prepared from natural essential oil extracted from plants. The compound essential oil comprises, by mass, 0.9-1.1% of niaouli essential oil, 1.8-2.2% of Eucalyptus essential oil, 1.8-2.2% of mint essential oil, 9-11% of tea tree essential oil, 9-11% of lavender essential oil and 72.5-77.5% of jojoba oil. Through reasonable material selection and an appropriate ratio, the compound essential oil for treating nasal part discomfort, throat discomfort and obstructed upper respiratory tract is obtained. The above components produce synergism so that effects of the components are improved. The compound essential oil can be used simply and can be directly used for skin and directly act a focus. An experiment proves that the compound essential oil can relieve nasopharynx and upper respiratory discomfort. The compound essential oil has a low cost and is conducive to large-area promotion.
The invention discloses a method for treating an infectious diabetes wound by using osmium nano-enzyme catalyzed by glucose response. It is characterized by GOx-OsNCs with triple enzyme activity, and can be used for treating diabetic infected wound. At a fixed glucose concentration (10 mmol/L) and a bacterial concentration (10)  8  CFU/mL), the antibacterial concentrations of GOx-OsNCs against Staphylococcus aureus and Escherichia coli were 25. Mu.g/mL and 100. Mu.g/mL, respectively. The coating, SEM characterization and live-dead staining all indicate that GOx-OsNCs have good antibacterial effect in the presence of glucose. Results of animal experimentsThe results show that GOx-OsNCs can effectively accelerate the healing of infected wounds of diabetic rats, and prove the feasibility of GOx-OsNCs treatment. In addition, GOx-OsNCs also have good biocompatibility, and can be used as a very potential material in the fields of biosensing, medical treatment and the like.
PROBLEM TO BE SOLVED: To further improve the safety of an embedment type injection pump having additional diaphragms for bolus injection. SOLUTION: The embedment type device for administration of a working fluid, more particularly a drug, has a chamber 3 for accepting the working fluid to be administered and a chamber 9 for accepting the working fluid bolus. Both chambers respectively have ports 6, 12 closed by the diaphragms 5, 11. An injection pipeline 8 communicating with an injection section is connected to an outlet 7 of the drug chamber 3. A supply pipeline 13 branched from the injection pipeline 8 is connected to the working fluid bolus accepting chamber 9. The supply pipeline 13 is internally provided with a mechanism 14 which opens a flow passage arriving at the injection section only when the working fluid bolus is supplied at a pressure higher than the prescribed min. pressure.  The occurrence of a condition to endanger the life by the sudden administration of a large amt. of the working fluid when the working fluid is kept supplied at all times only by the pressure lower than the min. pressure under which the flow passage is opened in order to replenish the drug storage section is eliminated. Even if the diaphragm of the drug storage section is mistaken with the diaphragm for the bolus injection, the liquid connecting path between the bolus injection chamber and the injection section is not held open and, therefore, the working fluid is not administrated.
BACKGROUND: Evidence about the association between albumin combined with neutrophil-to-lymphocyte ratio score (ANS) and survival outcomes in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is rare. This study aimed to evaluate the prognostic value of ANS in patients with ACS undergoing PCI by propensity score matching (PSM) analysis.
PATIENTS AND METHODS: Patients with ACS undergoing PCI were consecutively enrolled in this prospective cohort study from January 2016 to December 2018. The albumin and neutrophil-to-lymphocyte ratio cutoff values for predicting major adverse cardiovascular events (MACEs) were calculated using receiver operating characteristic curves. Survival analysis was performed using Kaplan-Meier estimates, the Cox proportional hazard regression models and PSM. The study endpoint was the occurrence of a MACE, which included all-cause mortality and rehospitalization for severe heart failure during follow-up.
RESULTS: Overall, 1549 patients with adequate specimens were identified and assigned into different groups for comparison. Before and after PSM, the Kaplan-Meier curves showed that a higher ANS value was associated with a higher risk of MACEs (all P  < 0.001). The multivariate Cox proportional hazard regression model showed that the ANS (per 1 score increase) [hazard ratio (HR), 2.016; 95% confidence interval (CI), 1.329-3.057; P  = 0.001 vs. HR, 2.166; 95% CI, 1.344-3.492; P  = 0.002] was an independent predictor for MACEs.
CONCLUSION: This study tentatively confirms that ANS may be a valuable clinical indicator to identify high-risk ACS patients after PCI. More high-quality prospective studies are needed in the future.
Part A is a single-arm, Phase 1, open-label, dose-escalation design in patients with NSCLC who have already been receiving crizotinib 250 mg by mouth (PO) twice daily (BID) for at least 8 weeks and are still tolerating treatment at that dose. Patients will continue treatment with crizotinib + escalating doses of AT13387 IV weekly for 3 weeks in a 4-week cycle. Each cohort will consist of at least 6 patients until the maximum tolerated dose (MTD) is reached. An additional 12 patients will be treated at the MTD level of AT13387 in combination with crizotinib to confirm the safety profile of the combination at that dose level.
Statistical Analysis: In the statistical analysis of the data obtained at the end of the study, SPSS (Statistical Package for Social Sciences / SPSS 21.0) was analyzed using the statistical program. In the study, arithmetic averages are presented with tables and graphs as mean ± SD (standard deviation) and values indicated by counting in numbers (percent). Demographic information of the participants and their responses to the questionnaire questions were evaluated using descriptive statistical analysis method. In the study, Independent Sample t Test was used in parametric data and ANOVA was used in normal non-parametric data. In all analyzes, p \<0,05 was considered statistically significant.

Sampling: Sample size was calculated based on the number of questions asked. Accordingly, the number of questions multiplied by the formula of 60 is the lower limit (42\*60=2520). Considering the 20% probability of a drop-out and the fact that participants did not want to volunteer, it was decided to take 3150 people to the study. Consent will be obtained from the participants through a voluntary information form.
The present invention relates to a data storage medium encoded with the corresponding structure coordinates of molecules and molecular complexes which comprise the active site binding pockets of IMPDH. Such data storage material is capable of displaying such molecules and molecular complexes, or their structural homologues, as a graphical three-dimensional representation on a computer screen. This invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. In addition, this invention relates to methods of using the structure coordinates to screen and design compounds, including inhibitory compounds, that bind to IMPDH or homologues thereof. This invention also relates to molecules and molecular complexes which comprise the active site binding pockets of IMPDH or close structural homologues of the active site binding pockets. This invention also relates to compounds and pharmaceutical compositions which are inhibitors of IMPDH.
Participants have access only to short-term interventions. Given access to all interventions at the end of the 5 weeks of the trial.
Children over 8 and under 18 with cystic fibrosis. Children must be represented by their parent.
PURPOSE:An improver for hypoxia, containing a specific benzoazepine derivative or a salt thereof as an active ingredient, having improving action on hypoxia and useful as a cerebral activator, drug for consciousness disorder caused by cerebrovascular disorder, etc., drug for senile dementia, etc. CONSTITUTION:An improver for hypoxia containing a benzoazepine derivative expressed by formula I (R<1> is H, lower alkyl, etc.; R<2> is phenyl which may have 1-3 substituent groups, e.g. halogen, lower alkyl, etc.; A is lower alkylene). specifically the improver can be effectively used as a cerebral activator, improving drug for consciousness disorder caused by cerebrovascular disorder, encephalitis, metabolic disorder, etc., drug for senile dementia and preventing agent for arrhythmia or cardiac failure caused by oxygen shortage, etc. The compound expressed by the formula is capable of removing active oxygen species, has also preventing action on formation of peroxide lipid in the living body and is useful as an antiarteriosclerotic agent, anti-inflammatory agent, remedy for cataract, etc.
<P>PROBLEM TO BE SOLVED: To provide an aqueous solution containing a sulfur-containing compound contained in a plant of Liliaceae, in a high content.  <P>SOLUTION: This aqueous solution containing the sulfur-containing compound contained in the plant of Liliaceae is provided. More concretely, the aqueous solution containing the sulfur-containing compound is obtained by immersing the plant of Liliaceae in an aqueous solution and extracting under an acidic condition. The aqueous solution containing the sulfur-containing compound can contain e.g. the sulfur-containing compound peculiar to the plant of Liliaceae such as allysine, etc., in a high content, since the sulfur-containing compound can be extracted into the solution from the plant body of the plant of Liliaceae in a good efficiency. In order to obtain such the aqueous solution, it is preferable to use the plant belonging to the genus Allium of Liliaceae, containing the sulfur-containing compound richly, and further preferable to use garlic or onion.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The carcinogenic potential of baricitinib was evaluated in Sprague-Dawley rats and Tg.rasH2 mice. No evidence of tumorigenicity was observed in male or female rats that received baricitinib for 91 to 94 weeks at oral doses up to 8 or 25 mg/kg/day, respectively (approximately 7 and 30 times the MRHD on an AUC basis). No evidence of tumorigenicity was observed in Tg.rasH2 mice that received baricitinib for 26 weeks at oral doses up to 300 and 150 mg/kg/day in male and female mice, respectively. 

Baricitinib tested negative in the following genotoxicity assays: the in vitro bacterial mutagenicity assay (Ames assay), in vitro chromosome aberration assay in human peripheral blood lymphocytes, and in vivo rat bone marrow micronucleus assay. 

Fertility (achievement of pregnancy) was reduced in male and female rats that received baricitinib at oral doses of 50 and 100 mg/kg/day respectively (approximately 62 and 93 times the MRHD in males and females, respectively, on an AUC basis) based upon findings that 7 of 19 (36.8%) drug-treated females with evidence of mating were not gravid compared to 1 of 19 (5.3%) control females. It could not be determined from the study design if these findings were attributable to toxicities in one sex or both. Fertility was unaffected in male and female rats at oral doses of 15 mg/kg and 25 mg/kg, respectively (approximately 13 and 26 times the MRHD on an AUC basis). However, maintenance of pregnancy was adversely affected at these doses based upon findings of increased post-implantation losses (early resorptions) and decreased numbers of mean viable embryos per litter. The number of viable embryos was unaffected in female rats that received baricitinib at an oral dose of 5 mg/kg/day and were mated to males that received the same dose (approximately 6 times the MRHD on an AUC basis). Reproductive performance was unaffected in male and female rats that received baricitinib at oral doses up to 50 and 100 mg/kg/day respectively (approximately 62 and 93 times the MRHD in males and females, respectively, on an AUC basis).
Subjects in the intervention arm will receive a 1 mg/kg bolus of methylene blue over 30 minutes, followed by an infusion of 0.15 mg/kg/h. The infusion rate may be increased in steps of 0.15 mg/kg/h every 30 minutes until a maximum of 0.5 mg/kg/h.
PURPOSE: To provide tablets or granules containing mesna as agent, and also provide a method for producing the tablets or granules. CONSTITUTION: This tablet contains mesna, a binder, swelling agent, lubricant and filler; the amounts of these ingredients to be used, based on 1 pt.wt. of the mesna, are as follows: 0.01-1 pt.wt., 0.03-0.4 pt.wt., 0.01-0.2 pt.wt., and 0.1-1 pt.wt., respectively. For a foamable tablet, there is additionally contained, other than the above ingredients, 0.05-30 pts.wt. of a physiologically nontoxic boiling agent in common use. In the case of granule, the ingredients are the same as those described above except the swelling agent.
During one part of the study (study phase A) patients will undergo hemodialysis (HD) treatments with Hemoscan over 2 weeks (Run-In period), followed by 12 HD sessions with HemoControl during the following 4 to 6 weeks. Separated by a one week wash out period, the same patients will be switched to On-Line Hemodiafiltration (HDF) treatments (study phase B), for a Run-In period of 2 weeks with Hemoscan, followed by 12 On-Line HDF sessions with HemoControl over the last 4 to 6 weeks of the study period.
Osteoarthritis (OA) is the most common degenerative joint disease worldwide, with the main pathological manifestation of articular cartilage degeneration. It have been investigated that pharmacological activation of transient receptor potential vanilloid 1 (TRPV1) significantly alleviated cartilage degeneration by abolishing chondrocyte ferroptosis. In this work, in view of the thermal activated feature of TRPV1, Citrate-stabilized gold nanorods (Cit-AuNRs) is conjugated to TRPV1 monoclonal antibody (Cit-AuNRs@Anti-TRPV1) as a photothermal switch for TRPV1 activation in chondrocytes under near infrared (NIR) irradiation. The conjugation of TRPV1 monoclonal antibody barely affect the morphology and physicochemical properties of Cit-AuNRs. Under NIR irradiation, Cit-AuNRs@Anti-TRPV1 exhibited good biocompatibility and flexible photothermal responsiveness. Intra-articular injection of Cit-AuNRs@Anti-TRPV1 followed by NIR irradiation significantly activated TRPV1 and attenuated cartilage degradation by suppressing chondrocytes ferroptosis. The osteophyte formation and subchondral bone sclerosis are remarkably alleviated by NIR-inspired Cit-AuNRs@Anti-TRPV1. Furthermore, the activation of TRPV1 by Cit-AuNRs@Anti-TRPV1 evidently improved physical activities and alleviated pain of destabilization of the medial meniscus (DMM)-induced OA mice. The study reveals Cit-AuNRs@Anti-TRPV1 under NIR irradiation protects chondrocytes from ferroptosis and attenuates OA progression, providing a potential therapeutic strategy for the treatment of OA.
TNF inhibitors (TNFi) have revolutionized the therapeutic management of various chronic immune-mediated inflammatory diseases. Despite their known benefits, these therapies are related to paradoxical adverse effects (PAEs), including paradoxical psoriasis (PP). Although the underlying mechanism remains somewhat unclear, some theories suggest that genetic factors, particularly certain single-nucleotide polymorphisms (SNPs), may play an important role. The present review aimed to research and analyze recent findings regarding the pathomechanisms involved in the appearance of PP and the association between various genetic factors and PP in individuals treated with TNFi. We performed a literature search and found that certain genes (IL23R, TNF, FBXL19, CTLA4, SLC12A8, TAP1) are strongly associated with the occurrence of PP in pediatric and adult patients during therapy with TNFi. The identification of the specific SNPs involved in the appearance of PP and other PAEs in patients treated with TNFi for various diseases and in different populations may later favor the recognition of those patients at a high risk of developing such adverse effects and could guide personalized therapeutic strategies in future years.
This is a single arm, prospective, open label clinical study, participants who fit inclusion/exclusion standards, completed physical anti-addiction treatments and surgical implantation standard will start DBS system stimulation and adjust parameters after 10-14 days of implantation. Then after stimulation for 9-32 weeks, they will be evaluated for treatment efficacies. This study is extendable, with agreements from participants, long term efficacy and safety follow-up study will be performed after 32 weeks ± 7 days of following, once every 2-3 months.
PCT No. PCT/EP93/01552 Sec. 371 Date Nov. 2, 1994 Sec. 102(e) Date Nov. 2, 1994 PCT Filed Jun. 17, 1993 PCT Pub. No. WO94/00531 PCT Pub. Date Jan. 6, 1994In accordance with the present invention a luminescent article is provided which luminescent article comprises a self-supporting or supported layer of phosphor particles dispersed in a binding medium and a protective coating thereover characterised in that the binding medium comprises one or more rubbery and/or elastomeric polymers, in that the ratio by volume of pigment to binding medium is at least 70:30 and at most 92:8 and the packing ratio is less than 67%. By said rubbery and/or elastomeric polymers the phosphor layer has improved elasticity of the screen, high protection against mechanical damage and thus high ease of manipulation and high pigment to binder ratio. Moreover no compression manipulation is necessary to get a thinner coated phosphor layer with reduced voids, and nevertheless a better image quality, i.a. sharpness, is obtained. One or more antioxidants may be present.
FIELD: medicine, chemical-pharmaceutical industry. SUBSTANCE: method involves extraction of larch or Douglas fir the milled wood that is carried out at ethyl acetate boiling point at ratio raw to ethyl acetate = 1:(5-8). Extraction process is carried out for 1-5 h. Obtained extract is filtered and evaporated up to the dry residue preparing that is mixed with benzine or hexane at mass ratio = 1:(8-20), respectively. Mixture is kept for 15-40 min at 18-24 C at stirring and solvent is distilled off. EFFECT: improved method of preparing. 2 cl